Biden cap on drug costs will save US seniors over $1,000 a year, study finds
Adds AARP expert in paragraph 6, patient in paragraphs 9-11
By Ahmed Aboulenein and Amina Niasse
WASHINGTON, Aug 28 (Reuters) -More than 1 million people in the U.S. will save over $1,000 a year beginning in 2025, when an annual $2,000 cap on prescription drug out-of-pocket costs kicks in, the leading lobbying group for older Americans said on Wednesday.
The cap, introduced as part of President Joe Biden's Inflation Reduction Act, applies to the Medicare program for people age 65 or over and those with disabilities. Its prescription drug component, known as Part D, provides coverage for around 56 million people.
AARP, which lobbied in favor of the law, commissioned health consultancy Avalere to conduct a study on the new benefit and published a report on the findings on Wednesday.
The $2,000 cap will lower prices in 2025 for more than 3.2 million people, or around 8.4% of Part D beneficiaries who do not receive other subsidies, AARP said in its report.
That represents a stark change from how Medicare Part D previously worked. Before the Inflation Reduction Act, beneficiaries who did not qualify for low income subsidies were required to pay 5% of drug costs regardless of how much they had already paid.
The cap is expected to provide long-term savings, particularly for those most in need, even if Part D premiums rise next year as expected, Leigh Purvis, an AARP prescription drug pricing expert, said during a press briefing.
By 2029, the lowered cap will help 4.1 million people, or around 9.6% of beneficiaries, AARP said.
The biggest impact will be felt by those who use high-priced, branded drugs the most.
Diana DiVito, 82, said the cost of the treatment she takes for chronic leukemia has averaged $858 per month over more than five years.
Her co-insurance was 33% of the drug's cost until she reached the Part D cap of several thousand dollars. After that, she still had to pay 5% of the drug's cost, DiVito said. In 2024, the law eliminated that additional payment.
"When I saw the first co-pay I almost had a heart attack," DiVito, an AARP member, said during the briefing. "It's a tremendous weight off my shoulders and I'm incredibly grateful."
Almost 40% of people who reach the cap between 2025 and 2029, some 1.4 million, will save more than $1,000 a year, including 420,000 people, or around 12%, who will save more than $3,000 annually. Currently, some patients pay over $10,000 a year, AARP said in its report.
The study excluded Part D beneficiaries who receive low income subsidies and pay nominal amounts for drugs from its analysis.
"The money seniors will no longer have to spend out-of-pocket is money they can invest in their families, broader health needs or simply save to achieve greater financial stability," AARP CEO Jo Ann Jenkins said.
Reporting by Ahmed Aboulenein in Washington and Amina Niasse in New York; Editing by Caroline Humer and Bill Berkrot
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.